The objective of this study is to evaluate the effect of DPP-4 inhibitors, used as adjunct therapy with insulin, compared to placebo alongside insulin, on HbA1c, blood glucose levels, C-peptide levels, daily insulin dosage, BMI, weight change, and adverse events in patients with type 1 diabetes. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.